Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
NCT06256705 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2025-09-22
Summary
Operandi project aims to address unmet clinical needs in the current management of GEP-NETs treated with PRRT by exploring new opportunities provided by imaging-based (AI algorithms) and data augmentation, simultaneous 68Ga-DOTATOC PET-MRI imaging, and novel approaches to increase patient selection and PRRT efficacy (genomic profiling, radiopotentiators, and new radionuclides). The study aim to identify predictive and early markers indicative of PRRT effectiveness based on a large prospective cohort of GEP-NET patients. This cohort will be used to uncover relevant predictive signatures within the morphological, functional, and molecular imaging data using novel imaging-based AI approaches with a new patient imaging pathway including simultaneous 68Ga-DOTATOC PET-MRI.
Considering this global objective, the objective of this clinical research protocol is to provide clinical, molecular and imaging data in a prospective standardized study, notably by performing systematic PET-MRI at baseline, at mid course of PRRT and 1 year after PRRT initiation, in patients with advanced GEP-NETs treated with PRRT.
Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Radiotherapy
Interventions
- OTHER
-
Simultaneous 68Ga-DOTATOC PET-MRI
on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-25
- Primary Completion
- 2028-03-25
- Completion
- 2029-09-25
Countries
- France
Study Locations
More Related Trials
-
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT04609592 ·Status: RECRUITING ·Phase: PHASE1
-
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)
NCT04790708 ·Status: UNKNOWN ·Phase: NA
-
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
NCT01873248 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
NCT07012330 ·Status: TERMINATED ·Phase: PHASE2
-
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
NCT04090034 ·Status: RECRUITING
-
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
NCT02231762 ·Status: COMPLETED ·Phase: PHASE2
-
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
NCT02736448 ·Status: TERMINATED ·Phase: PHASE2
-
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
NCT03273712 ·Status: COMPLETED ·Phase: PHASE2
-
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
NCT06045260 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma
NCT06691425 ·Status: RECRUITING ·Phase: NA
-
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
NCT02950025 ·Status: TERMINATED ·Phase: PHASE2
-
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
NCT03724409 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Personalized PRRT of Neuroendocrine Tumors
NCT02754297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
NCT01158170 ·Status: UNKNOWN ·Phase: PHASE3
-
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
NCT04242342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
NCT03575611 ·Status: SUSPENDED ·Phase: PHASE2
-
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
NCT05975593 ·Status: RECRUITING ·Phase: NA
-
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
NCT01030757 ·Status: TERMINATED ·Phase: PHASE2
-
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
NCT00955695 ·Status: UNKNOWN ·Phase: PHASE3
-
Stereotactic Volumetric Radiotherapy in Prostate Cancer
NCT02423889 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer
NCT01641497 ·Status: TERMINATED ·Phase: NA
-
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
NCT05387603 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation
NCT06218420 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
NCT03408665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA